CAR-T Therapy Shows Continued Success in Autoimmune Diseases Five Years After Lupus Breakthrough
Five years after German physician-scientist Georg Schett and collaborator Fabian Müller at the University of Erlangen-Nuremberg treated a young lupus patient with CAR-T cells, the patient remains in remission as of April 2026 and now works at the clinic where she was treated. The breakthrough case, which succeeded despite initial parental opposition and widespread fears that T cells would worsen autoimmune disease, has upended autoimmune treatment and driven a flood of experimentation and investment. Pharmaceutical companies now show huge interest in CAR-T therapy for autoimmune diseases, offering new hope to millions of patients beyond the therapy's original cancer applications.
Initial Lupus Breakthrough and Patient Recovery
▪Georg Schett's lupus patient achieved remission after CAR-T cell treatment.
▪Georg Schett treated a young lupus patient with CAR-T cells at the University of Erlangen-Nuremberg.
▪Georg Schett's lupus patient is working at the University of Erlangen-Nuremberg clinic where she was treated.
▪A widespread fear existed that T cells would trigger or worsen autoimmune disease.
▪Georg Schett's lupus patient has remained in remission for five years as of April 2026.
▪Georg Schett is a German physician-scientist at the University of Erlangen-Nuremberg.
▪The parents of Georg Schett's lupus patient initially opposed CAR-T cell treatment.
▪Fabian Müller is a collaborator of Georg Schett at the University of Erlangen-Nuremberg.
Transformation of Autoimmune Disease Treatment Landscape
▪Georg Schett's lupus patient case upended the world of autoimmune disease treatment.
▪CAR-T therapy for autoimmune diseases offers new hope to millions of patients.
▪The successful lupus CAR-T treatment drove a flood of experimentation in autoimmune disease.
▪Mouse studies raised the possibility that CAR-T cells could treat lupus before Georg Schett's patient case.
Pharmaceutical Industry Interest and Investment
▪There is a huge level of interest in CAR-T therapy for autoimmune diseases from pharmaceutical companies as of April 2026.
Perspective of Parents of Georg Schett's lupus patient
▪The parents of Georg Schett's lupus patient feared CAR-T cells would worsen their daughter's autoimmune condition.
Perspective of Pharmaceutical companies
▪Pharmaceutical companies see CAR-T therapy for autoimmune diseases as a commercially viable treatment area as of April 2026.
▪Pharmaceutical companies are investing heavily in CAR-T therapy research for autoimmune diseases following the lupus breakthrough.
Perspective of Autoimmune disease patients
▪Millions of autoimmune disease patients view CAR-T therapy as a potential path to long-term remission.
▪The five-year remission of Georg Schett's lupus patient represents a transformative outcome for autoimmune disease sufferers.
Story comments
Loading comments…